Document is current
Any future updates will be listed below
-
Authors
Sakakibara, Nana https://orcid.org/0000-0002-8387-8008
Nozu, Kandai
-
Funding
Funding for this research was provided by:
Kobe University
- License Information
-
More Information
Article History
Received: 21 December 2024
Revised: 5 March 2025
Accepted: 10 March 2025
First Online: 31 March 2025
Declarations
:
: Kandai Nozu is a member of advisory groups for Kyowa Kirin Co., Ltd., Toa Eiyo Ltd., Zenyaku Kogyo Co., Ltd., and Taisho Pharmaceutical Co., Ltd. Kandai Nozu has a patent for developing exon skipping therapy for Alport syndrome patients.Kandai Nozu also receives lecture fees from Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., Novo Nordisk Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Sumitomo Pharma Co., Ltd., Sanofi S.A., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, and Miyarisan Pharmaceutical Co., Ltd. Kandai Nozu receives speaker’s bureaus from Sumitomo Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sanofi S.A., Zenyaku Kogyo Co., Ltd., and Kyowa Kirin Co., Ltd. Finally, Kandai Nozu receives grants from Toa Eiyo Ltd., Zenyaku Kogyo Co., Ltd., and Torii Pharmaceutical Co., Ltd. Nana Sakakibara has nothing to disclose.
